Leading Robotic Prostate Cancer Surgeon and Researcher to Head Mount Sinai’s Urology Department
Dr. Ash Tewari named Director of Urology at Icahn School of Medicine at Mount Sinai.
Dr. Ash Tewari, one of the foremost leaders in robotic prostate surgery and prostate cancer research in the world, will serve as Chairman of The Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai, effective October 15, 2013.
“Dr. Tewari is a top-flight urologist and physician scientist of national and international repute who will position Mount Sinai as a urologic center of excellence, offering world-class urologic care, practice-changing research, and patient-centered care,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and President for Academic Affairs of the Mount Sinai Health System. “Dr. Tewari is known for his work in developing the fields of robotic prostatectomy, and outcomes research using novel medical imaging and genomics research.”
Dr. Tewari pioneered robotic prostatectomy and he has performed more than 5,000 robotic prostatectomies, and other minimally invasive procedures for various urological cancers. He has managed a robust urologic training program at New York Presbyterian Hospital-Weill Cornell Medical Center since 2004. Dr. Tewari has trained more than 30 fellows and residents in robotics and has made presentations on innovation in robotics at major medical meetings in the United States and around the globe.
Dr. Tewari comes to the Icahn School of Medicine at Mount Sinai after serving as Director of the Lefrak Center for Robotic Surgery at New York-Presbyterian Hospital/Weill Cornell Medical Center. Last year, the American Urological Association awarded him the prestigious Gold Cystoscope Award for his outstanding contributions to the field of urology and urologic oncology. Dr. Tewari has a solid commitment to research and has published in many peer reviewed journals. He is actively pursuing studies of the radiological phenotype of aggressive prostate cancer using novel imaging and genomics.
“My vision for the Department of Urology is to create a highly engaged team committed to world-class care, strong faculty and trainee development, and innovative research and discovery,” said Dr. Tewari.
Collaboration will be a core part of his vision, he explained. He anticipates partnerships with Departments including Surgery; Medical Oncology; Radiation Oncology, The Lillian and Henry M. Stratton-Hans Popper Department of Pathology; Obstetrics, Gynecology and Reproductive Sciences, Radiology, and the Tisch Cancer Center, as well as integrating activities with Institutes, such as The Charles Bronfman Institute of Personalized Medicine, and the Translational and Molecular Imaging Institute. He intends to build bridges with science and medicine leaders in New York and around the world.
“We will try to establish a seamless bed-to-bench side and bench-to-bedside model for our collaboration,” said Dr. Tewari.
Dr. Tewari was awarded his medical degree from the GSVM Medical College in Kanpur, India, where he received 18 gold medals and honors. He obtained specialized urologic training at the Sanjay Gandhi Post Graduate Institute in Lucknow, India; residency training at the Vattikuti Institute of Urology at Henry Ford Hospital in Detroit; as well as fellowships in urologic oncology at the University of California San Francisco and the University of Florida at Gainesville.
He is a member of the editorial board of the Gold Urology Journal and BJU International and is a reviewer for three urology peer-reviewed journals: the Journal of Urology, and the Journal of Endourology. In May, he published the authoritative textbook, Prostate Cancer: A Comprehensive Perspective.
Dr. Tewari has received numerous honors and awards from the American Urological Association and the Prostate Cancer Foundation. A leading light in urology circles, Dr. Tewari is an active member of many professional societies, notably the American Urological Association, the Society of Urologic Oncology, and the Society of Minimally Invasive Therapy and International Quality of Life Research.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
New AI Tool by Mount Sinai Researchers Could Reshape Prostate Cancer Care
Sep 23, 2024 View All Press Releases
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
May 14, 2022 View All Press ReleasesMount Sinai Receives $1 Million Grant for Prostate Cancer Research
Dec 05, 2019 View All Press Releases